Connect with us

Technology

Doceree Unveils Semmelweis: The First AI Model Purpose-Built for Pharma Commercialization

Published

1 day ago

on

General AI is built to be right about everything. Semmelweis is built to be right about the next prescription. The first-generation model is the intelligence layer beneath Daily Command and the Doceree product suite — and the first in a series named for the unsung pioneers of medicine.

SHORT HILLS, N.J., July 14, 2026 /PRNewswire/ — Doceree, the world’s first AI-powered operating system for healthcare marketing, today unveiled Semmelweis, its pharma-specific reasoning and orchestration model — the intelligence layer beneath Daily Command, the commercial operating system for pharma launched separately today, and the broader Doceree suite. Where general-purpose models understand the open web, Semmelweis is grounded in the signals that govern prescribing — clinical context, treatment pathways, and care behavior — and reads prescribing intent in real time through Clinical Intent Signals (CIS).

A name that carries a lesson

In the 1840s, the Hungarian physician Ignaz Semmelweis discovered that a simple act — doctors washing their hands — dramatically reduced deaths among mothers in childbirth, years before germ theory could explain why. He had the evidence, but the medical establishment rejected him; he was dismissed and ridiculed in his own lifetime, and vindicated only after his death as a founder of infection control.

Doceree chose the name deliberately: Semmelweis saw the signal before the industry was ready to believe it — precisely what the model is built to do. It is a first-generation model, and the first in a series named for the unsung pioneers of medicine.

“We could have shipped a feature and moved on,” said Harshit Jain, MD, Founder & Global CEO of Doceree. “We named it instead, because the lesson matters. Semmelweis saw the truth before medicine was ready for it. Our model is built to see the signal early — and to act on it only within the guardrails this industry rightly demands. It is the first model we have named. It will not be the last.”

Inside the model

Semmelweis does not compete with frontier models; it is built on them. The model draws on frontier systems for language and reasoning, then surrounds them with a proprietary architecture no general-purpose model can replicate:

Proprietary clinical grounding. Semmelweis reasons over deterministic clinical context — the ESPYIAN identity graph of more than six million verified HCPs, live Clinical Intent Signals, and 185+ direct EHR integrations — so it knows where a physician stands in a treatment decision instead of guessing from demographics.

A compliance-bounded action space. The model never touches patient data. It works only on de-identified, HCP-level context and can recommend only actions that already sit within medical, legal, and regulatory guidelines — advisory, human-approved, auditable, MLR-ready by design.

A closed measurement loop. Each outcome the model observes informs its next recommendation, so its precision improves with every campaign.

Why a general model can’t

The defensibility has never resided in the base model — frontier weights are licensed, and they commoditize by the quarter. The advantage lies in everything built around them, and it strengthens with use. Semmelweis distinguishes between a physician researching a therapy and one about to prescribe it — a distinction no open-web model can make. It treats privacy and regulation not as limitations but as the operating platform itself, which is what lets it be specific where a general model stays generic. And it sits above the DSPs, networks, and channels, orchestrating across them rather than working inside any one — the altitude that makes Daily Command an operating system rather than a point solution.

One model, the entire suite

Semmelweis provides the intelligence; Doceree’s products are where it is applied. It is the reasoning engine behind Daily Command, standing in the same relationship to it that a foundation model holds to the application built on it. It reasons across the Clinical Intent Suite, where CIS detects clinical intent as it forms. It extends into RepTwin’s AI field agents, into Co-pay.com at the point of fill, and across every channel in the Doceree Marketplace. Across all of it, the model optimizes toward the filled — and refilled — prescription, the outcome that actually advances a therapy, rather than stopping at the impression or the claim.

“Our clients never see the model, they see what it makes possible,” said Kamya Elawadhi, Co-Founder & President of Doceree. “Recommendations that arrive grounded in clinical context, human-approved, and ready for MLR, built for the way pharma actually works, not adapted to it. And because one model runs beneath every Doceree product, that standard follows our clients everywhere they work with us.”

Availability

Semmelweis is in production today beneath Daily Command and the Doceree suite. Daily Command onboarding is open at doceree.com/daily-command.

About Doceree

Doceree is the only healthcare marketing platform that can measure and adapt to the actual clinical intent of both physicians and patients. Built on the industry’s largest real-time clinical signal network, Doceree’s infrastructure unifies the entire healthcare journey — from physician awareness to prescription and patient fill to refill. Learn more at doceree.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/doceree-unveils-semmelweis-the-first-ai-model-purpose-built-for-pharma-commercialization-302825341.html

SOURCE Doceree

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment

Published

45 minutes ago

on

July 15, 2026

By

WASHINGTON, July 15, 2026 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant), the first new prescription medication approved for prevention of vomiting induced by motion in 47 years, will sponsor the No. 47 entry in the NTT IndyCar Series with Rahal Letterman Lanigan Racing.

The partnership aligns NEREUS’™ breakthrough innovation in motion relief with the high-speed world of IndyCar racing, where focus and stability are essential.

This sponsorship marks a symbolic milestone: 47 years since the last new motion sickness treatment was introduced in the United States. NEREUS™ represents a modern advancement as a selective NK-1 receptor antagonist designed to prevent vomiting induced by motion, offering a new option for millions who experience motion sickness during travel.

“Partnering with the No. 47 car perfectly captures this historic moment and our shared commitment to performance under challenging conditions,” said Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of the Board of Vanda. 

The NEREUS™-branded No. 47 IndyCar will feature prominent sponsorship visibility across select NTT IndyCar Series events in 2026.

About NEREUS™ (tradipitant)

NEREUS™ is an oral NK-1 receptor antagonist FDA-approved for the prevention of vomiting induced by motion in adults. It is the first new pharmacologic treatment approved for this indication in over four decades.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

About Rahal Letterman Lanigan Racing

Rahal Letterman Lanigan Racing is a championship-winning team competing in the NTT IndyCar Series.

Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com 

Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com

Follow us on X @vandapharma

View original content to download multimedia:https://www.prnewswire.com/news-releases/nereus-powers-forward-sponsors-no-47-indycar-entry-celebrating-47-years-since-last-new-us-motion-sickness-treatment-302826721.html

SOURCE Vanda Pharmaceuticals Inc.

Continue Reading

Technology

VIAVI Announces Date for Fiscal Fourth Quarter and Fiscal Year 2026 Financial Results

Published

45 minutes ago

on

July 15, 2026

By

CHANDLER, Ariz., July 15, 2026 /PRNewswire/ — Viavi Solutions Inc. (VIAVI) (NASDAQ: VIAV) will announce its fiscal fourth quarter and fiscal year 2026 financial results for the period ended June 27, 2026, on Wednesday, August 5, 2026, after the close of market.

The Company will host an earnings call at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast of the call and the replay will be available on the VIAVI website at https://investor.viavisolutions.com. The quarterly earnings press release, supplementary slides and historical financial tables will be posted under the “Quarterly Results” section.

To participate via telephone:

Toll-Free Dial-In Number:

1 (833) 461-5787

Toll Dial-In Number:

1 (585) 542-9983

Conference ID:

687 725 628

About VIAVI Solutions
VIAVI (NASDAQ: VIAV) is a global leader in test and measurement and optical technologies. Our test, monitoring, assurance, and resilient position, navigation and timing solutions enable and secure critical infrastructure ranging from data center ecosystems and communication networks to military, aerospace, railway and first responder communications. In addition, we develop and advance technologies used in high-volume optical applications across anti-counterfeiting, consumer electronics, aerospace, industrial and automotive end markets.

Learn more about VIAVI at www.viavisolutions.com. Follow us on VIAVI Perspectives, LinkedIn and YouTube.

Investors Contact:
Vibhuti Nayar, 408-404-6305; investor.relations@viavisolutions.com
Press Contact:
Amit Malhotra, 202-341-8624; amit.malhotra@viavisolutions.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/viavi-announces-date-for-fiscal-fourth-quarter-and-fiscal-year-2026-financial-results-302822275.html

SOURCE VIAVI Financials

Continue Reading

Technology

The American Council of the Blind to Distribute Ray-Ban Meta AI Glasses to Blind Veterans in St. Louis on July 27

Published

45 minutes ago

on

July 15, 2026

By

ALEXANDRIA, Va., July 15, 2026 /PRNewswire/ — The American Council of the Blind is proud to partner with Meta and the Blinded Veterans Association (BVA) to distribute Ray-Ban Meta AI glasses to eligible veterans who are blind during the upcoming 2026 ACB Conference and Convention in St. Louis.

The distribution will take place on Monday, July 27, from 1 to 5 p.m. CT at the Hyatt St. Louis at The Arch in downtown St. Louis. Eligible veterans can receive Ray-Ban Meta AI glasses at no cost while supplies last and a complimentary day pass to the ACB convention for July 27.

The initiative is part of Meta’s commitment to donate Ray-Ban Meta AI glasses to 130,000 blinded veterans worldwide, expanding access to technology that can support greater independence, access to information, and everyday tasks. As a distribution partner, ACB will also provide access to training resources for veterans receiving Meta glasses.

“Supporting veterans who are blind or have low vision has long been an important part of ACB’s mission,” said ACB Executive Director Scott Thornhill. “We are honored to partner with Meta and BVA to help connect veterans with innovative technology that can make a meaningful difference in their daily lives.”

Ray-Ban Meta AI glasses combine a lightweight, hands-free design with built-in artificial intelligence to help users complete everyday tasks more independently. Wearers can ask the glasses to describe their surroundings, read printed text, identify objects, and capture photos or videos.

To receive a pair of Ray-Ban Meta AI glasses at the July 27 distribution event, individuals must provide proof of military service, acknowledge legal blindness, and own a compatible smart phone.

A day pass to the ACB Conference and Convention with access to the Exhibit Hall will be available for recipients.

For more details about the Ray-Ban Meta AI glasses distribution, visit https://www.acb.org/glasses.

About the American Council of the Blind

The American Council of the Blind is a national member-driven consumer organization representing Americans who are blind or have low vision. With 65 affiliates, ACB strives to increase independence, security, equality of opportunity, and to improve the quality of life for all people who are blind or have low vision. For more information, visit https://www.acb.org.

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-american-council-of-the-blind-to-distribute-ray-ban-meta-ai-glasses-to-blind-veterans-in-st-louis-on-july-27-302826844.html

SOURCE American Council of the Blind

Continue Reading

Trending